When it comes to life sciences, the industry itself is inherently global—which means the work that gets done must also reflect this reality. A single therapy might be discovered in the U.S., tested across Europe and Asia, manufactured using ingredients sourced from multiple continents, and distributed worldwide.
In fact, more than half of FDA-regulated manufacturing facilities are located outside the United States, spanning more than 150 countries—highlighting just how international the ecosystem has become.
This level of coordination is not incidental. It reflects how the industry operates day to day. The science may start in a lab, but getting a treatment to patients requires a network that moves across borders.
What Life Sciences Work is Done Globally?
Nearly every phase of the life sciences lifecycle now depends on cross-border collaboration—it’s probably easier to ask what work isn’t done globally.
Clinical trials are a clear example. As of May 2026, ClinicalTrials.gov lists over 585,000 registered studies across 225 countries and territories, with 57% conducted entirely outside the U.S. This shift reflects a need for more diverse patient populations and faster enrollment timelines, both of which are difficult to achieve in a single geography.
Beyond trials, manufacturing and supply chains are equally distributed. Pharmaceutical production often involves raw materials sourced in one region, active ingredients produced in another, and final product manufacturing elsewhere. A single medical product can involve multiple parties across different countries at various stages of production.
R&D collaboration follows the same pattern. Globally, R&D investment exceeded $3.1 trillion in 2022 across major economies, reinforcing how innovation depends on coordinated effort across regions.
Put simply: the life sciences industry is global both in reach and execution.
How Work Actually Gets Done Across Borders
Executing work across regions requires structure—just look at multi-regional clinical trials (MCRTs). These studies are designed to generate data across geographic regions simultaneously, allowing regulators like the FDA and international counterparts to evaluate therapies more efficiently.
Regulatory alignment plays a key role. Agencies such as the FDA, EMA, and others routinely share inspection findings, conduct joint reviews, and align on Good Clinical Practice (GCP) standards for clinical data. This ensures that data collected in one region can be trusted and used in another.
On the operational side, companies are moving toward more flexible delivery models. Teams are no longer built around a single location. Instead, work is allocated based on where the right expertise exists. That could mean clinical monitoring in one region, data management in another, and regulatory support somewhere else entirely.
Outsourcing is part of this shift. Today, a significant portion of clinical research is conducted with outsourced support, reflecting the need for specialized expertise and flexible scaling across locations.
Benefits of Globalization in Life Sciences
When done right, global collaboration changes how quickly and efficiently life sciences work gets done. Let’s take a look at some of the key benefits offered from cross-border execution.
Faster Clinical Development
Running trials across multiple countries expands the patient pool, accelerating recruitment and shortening timelines. It also enables simultaneous regulatory submissions in multiple markets.
Stronger, More Representative Data
Diverse patient populations lead to more reliable safety and efficacy insights, improving the likelihood of regulatory approval across regions. Trials that include patients from different areas produce results that are more broadly applicable across populations.
Access to Specialized Talent
The complexity of modern drug development requires niche expertise—biostatistics, regulatory affairs, AI-driven analytics—that may not exist in a single location. Global delivery models unlock access to these specialized capabilities at scale.
Greater Innovation Through Collaboration
Research shows that innovation increasingly emerges from networks of collaborating organizations rather than isolated teams. Cross-border teamwork allows organizations to combine knowledge, technology, and perspectives that wouldn’t exist otherwise.
Challenges That Arise When Life Sciences Goes Global
Despite its advantages, global execution also introduces certain complexities. By being aware of these issues, you can approach them with the right strategy and support.
Regulatory Fragmentation
Each country has its own requirements for approvals, ethics reviews, and data reporting. Navigating these differences can slow down progress if not properly managed.
Data Privacy and Compliance Risks
Strict regulations like Europe’s General Data Protection Regulation (GDPR) impose limitations on how patient data is stored and transferred across borders—forcing organizations to design systems that meet multiple legal frameworks simultaneously.
Operational and Logistical Complexity
Day-to-day operations can also become harder to manage. Time zone differences, language barriers, and local infrastructure all affect how work moves forward.
Supply Chain Vulnerabilities
Globalization increases exposure to supply chain risks. When production and sourcing are spread globally, disruptions in one region can affect the entire system.
Navigating a Global Life Sciences Landscape
Success in global life sciences comes down to how well organizations integrate their cross-border operations. The most effective organizations focus on three things:
- Coordinated global strategy: Rather than treating each region independently, leading companies design unified operating models that align R&D, clinical, regulatory, and manufacturing functions across markets.
- Flexible delivery models: Blended teams—combining onshore oversight with offshore or nearshore execution—allow organizations to scale efficiently without sacrificing quality.
- Strong governance & partnership: Managing compliance, timelines, and quality across regions requires structured oversight and trusted partners who understand both local and global dynamics.
This is where functional service provider (FSP) models are gaining traction. By outsourcing specific functions—like clinical operations, data management, or regulatory support—organizations can tap into global talent while maintaining control over performance.
Make Globalization Work for You
Success in life sciences depends on global collaboration. And that’s not changing anytime soon. The difference between organizations that struggle and those that move forward comes down to execution. Teams need the right structure, the right talent, and a clear way to manage work across regions without slowing progress.
As a functional service provider, Insight Global helps life sciences organizations operate confidently across borders. By aligning specialized talent with global delivery models, we help teams scale critical functions, stay compliant in complex regulatory environments, and keep timelines on track.
If your organization is facing difficulties in a global life sciences landscape, it may be time to bring in additional support from a true partner—like Insight Global. Contact us to learn more.
by Julia Koslowsky 
by Insight Global Staff 
